Our understanding of the preventative and therapeutic potentialof targeting PPARγ with thiazolidinediones is largelylimited by several factors, including the lack of (a) experimental usage ofdistinct models of colitis, (b) understanding of tissue specific roles of PPARγ in different models of colonicinflammation, (c) understanding of factors affecting thiazolidinedione efficacy(PPARγ levels, etc.), (d) understanding of the mechanism of the anti-inflammatoryactions of PPARγ, and (e) understanding of the adverse effects of short- and long-termuse of thiazolidinediones during inflammation. This evidence concerns the gene PPARG and colitis.